Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.43 |
| ▸ | SCN7A | Q01118 | 2/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3355208 | 0.87 | KCNH2 (0.40) | KCNH2SCN7AHRH2HRH1HRH3 | |
| SCHEMBL3383404 | 0.87 | KCNH2 (0.40) | KCNH2SCN7AHRH2HRH1HRH3 | |
| SCHEMBL3358891 | 0.87 | KCNH2 (0.40) | KCNH2SCN7AHRH2HRH1HRH3 | |
| SCHEMBL3353344 | 0.85 | KCNH2 (0.48) | KCNH2 | |
| SCHEMBL4441211 | 0.84 | KCNH2 (0.57) | KCNH2SCN7AHRH2HRH1HRH3 | |
| SCHEMBL3355195 | 0.84 | KCNH2 (0.57) | KCNH2SCN7AHRH2HRH1HRH3 | |
| SCHEMBL3353433 | 0.84 | KCNH2 (0.57) | KCNH2SCN7AHRH2HRH1HRH3 | |
| SCHEMBL3355824 | 0.84 | KCNH2 (0.57) | KCNH2SCN7AHRH2HRH1HRH3 | |
| Trifluoroacetic Acid SCHEMBL3355836 | 0.78 | KCNH2 (0.52) | KCNH2SCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL4441819 | 0.77 | KCNH2 (0.39) | KCNH2SCN7ASCN5ASCN2ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144717-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE-DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| EP-2121702-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE- DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008071961-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE- DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144717-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE-DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | NQO2, SDHA, NDUFS5 | KCNH2 466/4885SCN7A 538/4885HRH2 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.